Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441668 | 0.88 | MAOB (0.43) | ALOX5SRD5A2ALDH1A1MAOBMEN1 | |
| SCHEMBL2447545 | 0.87 | SRD5A2 (0.43) | ALOX5SRD5A2PTGER3PTGDRMRGPRX4 | |
| SCHEMBL2021908 | 0.81 | NOTUM (0.55) | ALOX5SRD5A2ALDH1A1MAOBHPGD | |
| SCHEMBL2021478 | 0.77 | SRD5A2 (0.43) | ALOX5SRD5A2KDM4EALDH1A1MRGPRX4 | |
| SCHEMBL2207602 | 0.70 | ALOX5 (0.43) | ALOX5SRD5A2MRGPRX4MAOBSLC16A3 | |
| Potassium Ion SCHEMBL2447150 | 0.68 | MAOB (0.47) | SRD5A2MAOBMEN1KMT2ACA12 | |
| SCHEMBL2016768 | 0.68 | SRD5A2 (0.50) | ALOX5SRD5A2PTGER3PTGDRKDM4E | |
| SCHEMBL2016771 | 0.68 | SRD5A2 (0.50) | ALOX5SRD5A2PTGER3PTGDRKDM4E | |
| SCHEMBL16918467 | 0.68 | SRD5A2 (0.50) | ALOX5SRD5A2PTGER3PTGDRKDM4E | |
| SCHEMBL9737786 | 0.68 | ALOX5 (0.41) | ALOX5SRD5A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150336966-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2542554-B1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARM INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-9108969-B2 | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9085581-B2 | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof | ARENA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130184307-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8415484-B2 | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2542554-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011109471-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-2342205-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals ,Inc. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010027431-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336966-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | ALOX5 182/4885SRD5A2 717/4885PTGER3 572/4885 |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | ALOX5 182/4885SRD5A2 717/4885PTGER3 572/4885 |
| US-20130184307-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | ALOX5 182/4885SRD5A2 717/4885PTGER3 572/4885 |
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | S1PR1, S1PR5, S1PR2 | ALOX5 186/4885SRD5A2 692/4885PTGER3 998/4885 |
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | S1PR1, S1PR5, S1PR2 | ALOX5 183/4885SRD5A2 677/4885PTGER3 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.